CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
Junho Kang, Jae Ho Jeong, Hee-Sang Hwang, Sang Soo Lee, Do Hyun Park, Dong Wook Oh, Tae Jun Song, Ki-Hun Kim, Shin Hwang, Dae Wook Hwang, Song Cheol Kim, Jin-hong Park, Seung-Mo Hong, Kyu-pyo Kim, Baek-Yeol Ryoo, Changhoon Yoo
Cancer Research and Treatment. 2020;52(2):594-603.   Published online 2019 December 18    DOI: https://doi.org/10.4143/crt.2019.493

Excel Download

Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
Cancer Research and Treatment. 2020;52(2):594-603   Crossref logo
Link1 Link2 Link3

Efficacy and Safety of S-1 as Second-Line Chemotherapy for Patients with Advanced Biliary Tract Cancer
Annals of Oncology. 2012;23:xi121   Crossref logo
Link1 Link2

In response to She et al., “Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater”
Lung Cancer. 2020;146:385-386   Crossref logo
Link1 Link2

Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine
Cancer Science. 2017;109(1):215-224   Crossref logo
Link1 Link2

Su1143 EFFICACY AND SAFETY OF PEMBROLIZUMAB FOR GEMCITABINE/CISPLATIN-REFRACTORY BILIARY TRACT CANCER: A MULTICENTER RETROSPECTIVE STUDY
Gastroenterology. 2020;158(6):S-522-S-523   Crossref logo
Link1 Link2

Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study
Journal of Clinical Medicine. 2020;9(6):1769   Crossref logo
Link1

525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028
European Journal of Cancer. 2015;51:S112   Crossref logo
Link1 Link2

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program
BMC Cancer. 2019;19(1):   Crossref logo
Link1 Link2 Link3

High PD-L1 expression is associated with treatment response to pembrolizumab in patients with advanced biliary tract cancer
Annals of Oncology. 2019;30:v279-v280   Crossref logo
Link1 Link2 Link3

High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
Scientific Reports. 2020;10(1):   Crossref logo
Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.